SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis - update from 2017 to 2023

Chukwudile, B; Pan, D; Silva, L; Gogoi, M; Al-Oraibi, A; Bird, P; George, N; Thompson, HA; Baggaley, RF; Hargreaves, S; et al. Chukwudile, B; Pan, D; Silva, L; Gogoi, M; Al-Oraibi, A; Bird, P; George, N; Thompson, HA; Baggaley, RF; Hargreaves, S; Pareek, M; Nellums, LB (2024) Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis - update from 2017 to 2023. ECLINICALMEDICINE, 75. p. 102801. ISSN 2589-5370 https://doi.org/10.1016/j.eclinm.2024.102801
SGUL Authors: Hargreaves, Sally

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview
[img] Microsoft Word (.docx) (Supplementary Tables and Figures) Supplemental Material
Download (831kB)

Abstract

Background Antimicrobial resistance (AMR) is a critical global health concern. A previous systematic review showed that migrants in Europe are at increased risk of AMR. Since the COVID-19 pandemic there have been rapid changes in patterns of antibiotic use, AMR, and migration. We aimed to present an updated evidence synthesis on the current distribution of AMR among migrants in Europe. Methods We carried out a systematic review and meta-analysis in accordance with PRISMA guidelines (PROSPERO ID: CRD42022343263). We searched databases (MEDLINE, Embase, PubMed and Scopus) from 18 January 2017 until 18 January 2023 to identify primary data from observational studies reporting any laboratory-confirmed AMR among migrants in the European Economic Area (EEA) and European Union-15 (EU-15) countries using over 7 key search terms for migrants and over 70 terms for AMR and countries in Europe. Outcomes were infection with, or colonisation of AMR bacteria. Methodological quality was assessed using Joanna Briggs Institute Critical Appraisal Checklist for Observational Studies. We meta-analysed the pooled-prevalence of infection and/or colonisation of AMR organisms. Findings Among 630 articles, 21 observational studies met the inclusion criteria and were included in this review. The pooled prevalence for any detected AMR was 28.0% (95% CI 18.0%–41.0%, I2 = 100%) compared to a 25.4% seen in the previous review; gram-negative bacteria 31.0% (95% CI 20.0%–44.0%, I2 = 100%), and methicillin-resistant staphylococcus aureus 10.0% (95% CI 5.0%–16.0%, I2 = 99%). Drug-resistant bacteria were more prevalent in community settings in large migrant populations (pooled prevalence: 41.0%, 95% CI 24.0%–60.0%, I2 = 99%) than in hospitals (21.0%, 95% CI 12.0%–32.0%, I2 = 99%). AMR estimates in ‘other’ migrants were 32.0%, (95% CI 12.0%–57.0%, I2 = 100%) and 28.0% (95% CI 18.0%–38.0%, I2 = 100%) in forced migrants. No firm evidence of AMR acquisition with arrival time or length of stay in the host country was found. Interpretation Studies investigating AMR in migrants are highly heterogenous. However, since the COVID-19 pandemic, migrants may be at higher risk of acquiring resistant bacteria, particularly gram-negative bacteria, within community settings such as refugee camps and detention centres in Europe. Our study highlights the importance of infrastructure and hygiene measures within these settings, to mitigate transmission of resistant pathogens. Policy-makers should screen for AMR in migrants prior to departure from countries of origin, where feasible, and upon arrival to a new country to ensure optimal health screening, infection control and effective treatment.

Item Type: Article
Additional Information: Copyright © 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Antimicrobial resistance, Bacteria, Migrants, Refugees, Europe/EU-15 or EEA
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
?? 61 ??
Journal or Publication Title: ECLINICALMEDICINE
ISSN: 2589-5370
Dates:
DateEvent
5 September 2024Published
12 August 2024Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
NIHR302338National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
UNSPECIFIEDNIHR Leicester Biomedical Research Centrehttp://dx.doi.org/10.13039/501100020013
UNSPECIFIEDNIHR Applied Health Collaboration East MidlandsUNSPECIFIED
NIHR300072National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
SBF005l1Academy of Medical Scienceshttp://dx.doi.org/10.13039/501100000691
LCF/PR/SP21/52930003'la Caixa' Foundationhttp://dx.doi.org/10.13039/100010434
UNSPECIFIEDResearch EnglandUNSPECIFIED
UNSPECIFIEDMedical Research Councilhttp://dx.doi.org/10.13039/501100000265
UNSPECIFIEDWorld Health Organizationhttp://dx.doi.org/10.13039/100004423
Web of Science ID: WOS:001309219100001
URI: https://openaccess.sgul.ac.uk/id/eprint/116821
Publisher's version: https://doi.org/10.1016/j.eclinm.2024.102801

Actions (login required)

Edit Item Edit Item